Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
PDS Biotechnology develops innovative immunotherapies targeting cancer and infectious diseases. Its core platform, Versamune, stimulates potent, tumor-specific T cell responses with a favorable safety profile. The company focuses on cancer treatments, including HPV-related and resistant cancers, and vaccines for infectious diseases like influenza. Its business model combines proprietary immunotherapy platforms with strategic collaborations to advance targeted, immune-based therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.